Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVE5026 versus enoxaparin for venous thromboembolism prevention after elective total hip replacement
2007-007944-80Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing AVE5026 with Enoxaparin (2 arms). Primary endpoint: Primary efficacy endpoint. Started Mar 2008; status: completed.
02
Drugs
semuloparinenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2007-007944-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007944-80.